American Shared Hospital Services is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in San Francisco, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $28 million and a loss of $3 million (its filed statements).
Usage businessServices-Medical LaboratoriesSan Francisco, CAfilings since 19958 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 2.9 out of ten, present 5.5 out of ten, future 4.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.2 out of ten. 5 warning events since 2017; the latest 2026-06-04. 2nd percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.8 out of ten. +4.6% a year over 9 filed years; profitable in 7 of 9. 38th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.3 out of ten. Share count grew 1.6% a year. 0% of cash flow returned. Insiders: 0 sales, 1 purchases. 53rd percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 5.9 out of ten. ROE -6%: lost 6¢ per shareholder dollar. Leverage 50%: owes 50¢ per asset dollar. 59th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.9 out of ten. bottom 49% of 23 in its family; net margin -5.5%. 49th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 6.0 out of ten. CrossAssetData estimate 6.0/10, confidence 20 of 100 (family median). 50th percentile among 20 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 3.0 out of ten. bottom 30% of 23 in its family for room to expand. 30th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.6 out of ten. top 34% of 23 in its family for growth drivers. 66th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 1.9 out of ten. bottom 19% of 20 in its family for expectations against reality. 19th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-31 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-13 (on EDGAR). Newest filing: Form 10-Q, 2026-08-13. Filings on record since 1995. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Direct Patient Services 55%, Medical Equipment Leasing 45%. As tagged in its annual report (Form 10-K, filed 2026-03-31).
Who runs it
Stachowiak, Raymond C (Executive Chairman); Tirrito, Alexis (Interim CFO, CAO and Secretary). 2 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.